Skip to main content

Sensus Healthcare Collaborates with CureRays to Provide Oversight to Help Customers Assure Patient Safety, Reliability of Outcomes and Conformance with Regulatory Requirements

Physician-run radiation oncology innovator also to research new indications and broaden the market for SRT to include inflammatory diseases

BOCA RATON, Fla., Feb. 06, 2024 (GLOBE NEWSWIRE) --  Sensus Healthcare, Inc. (Nasdaq: SRTS), a medical device company specializing in highly effective, non-invasive, minimally-invasive and cost-effective treatments for oncological and non-oncological conditions, announces a new multi-faceted collaboration with CureRays, a radiation oncology specialist organization based in Atlanta and Grass Valley, Calif. 

Under the collaboration, CureRays will provide Sensus’ dermatology customers with oversight and supervision to assure patient safety, quality, reliability of outcomes and conformance with regulatory requirements, in particular in states where regulations covering the use of ionizing radiation have been tightened.  In addition, CureRays will research new indications for Sensus’ superficial radiotherapy (SRT and IG-SRT), including inflammatory diseases.

“This collaboration is the culmination of several years of discussion that started early in the COVID-19 pandemic, when we learned that Drs. Khan and Hess were treating COVID pneumonia with low-dose radiotherapy for infectious and inflammatory diseases.  We were anxious to help stem fatalities in any way we could, and we’ve been impressed with their commitment to patient care.  CureRays is well-versed in our SRT-100 Vision® (IG-SRT) system, which they are utilizing to treat skin cancer and keloids,” commented Joe Sardano, chairman and chief executive officer of Sensus.

“CureRays’ expertise in radiotherapy and their commitment to continuing education led us to engage them to help our dermatologist customers navigate the complex and changing requirements of radiotherapy,” he added. “In addition, we are thrilled to support their efforts to expand the use of our products and broaden our markets, beginning with arthritis.”

CureRays is led by Mohammad K. Khan, M.D., Ph.D., Professor of Medicine, Department of Radiation Oncology at the Emory University School of Medicine, and Clayton Hess, M.D., M.P.H., Medical Director, Radiation Oncology at Sierra Nevada Memorial Hospital in Grass Valley.  Dr. Khan serves on the Sensus Medical Advisory Board and Dr. Hess treats patients with a recently-purchased SRT 100-Vision (IG-SRT) at CureRays’ Grass Valley facility.  CureRays is focused on three main endeavors – radiation treatments for patients, radiation consulting for physicians and the conduct of clinical trials.

Dr. Khan said, “As a member of the Sensus Healthcare Medical Advisory Board, I am fully aware of the many benefits of a portable device to treat skin cancer.  This portability is a key component of SRT’s utility, not only for treating skin cancers, but also for other indications, especially those where patients can be treated bedside or closer to home within their community. CureRays is very excited about the possibility of supporting clinical expansion by investigating SRT beyond its current indications to include a host of malignant and benign conditions.”

Dr. Khan added, “The initial focus on rheumatoid arthritis is driven by four decades of evidence in Europe, where low-dose radiation is standard-of-care in Germany. We will be exploring the use of low-dose radiotherapy in indications where we can control the immune system and inflammation with minimal impact to body structures.”

Dr. Hess said, “SRT has been successfully treating skin cancer for years. It’s the best alternative to surgery for non-melanoma skin cancer.  As a practitioner in a small town in the Sierra Nevada foothills, my vision is to bring a non-scaring and effective treatment option not only to my patients, but to support the wider use of SRT in small communities across the United States, not just in large metropolitan areas. My goal is also to help further enhance patient selection against the risks and benefits of radiotherapy.”

About Sensus Healthcare

Sensus Healthcare, Inc. is a global pioneer in the development and delivery of non-invasive treatments for skin cancer and keloids. Leveraging its cutting-edge superficial radiotherapy (SRT and IG-SRT) technology, the company provides healthcare providers with a highly effective, patient-centric treatment platform. With a dedication to driving innovation in radiation oncology, Sensus Healthcare offers solutions that are safe, precise, and adaptable to a variety of clinical settings. For more information, please visit

LHA Investor Relations
Kim Sutton Golodetz

#   #   #

Primary Logo

Data & News supplied by
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.